
In 2 pivotal phase 3 studies, all 5 readers hit sensitivity and specificity targets for florquinitau F 18 tau PET, including in patients with early symptomatic Alzheimer disease.
VITAL™ VIDEO SERIES
|
MEET THE FACULTY
|
RESOURCES AND LINKS
© Janssen Pharmaceuticals, Inc. 2011. All rights reserved.



